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by 
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Alzheimer’s disease (AD) is symptomized by amyloid-beta plaques in the brain and accounts 
for more than 65 percent of dementia cases. Vitamin B12 (cobalamin) deficiency can result in 
similar cognitive impairment and roughly 15% of the elderly are vitamin B12 deficient. 
Vitamin B12 deficiency results in the accumulation of toxic methylmalonic acid and 
homocysteine. Hyperhomocysteinemia is a strong risk factor for AD. To test if vitamin B12 
deficiency stimulates amyloid-beta toxicity, Caenorhabditis elegans expressing amyloid-beta 
in muscle were fed either vitamin B12-deficient OP50-1 or vitamin B12-rich HT115(DE3) E. 
coli bacteria. Increased amyloid-beta toxicity was found in worms fed the 0P50-1 diet. 
Supplementation of the OP50-1 diet with vitamin B12 did not rescue the increased C. elegans 
toxicity. Knockdown of either of the only two C. elegans vitamin B12-dependent enzymes 
metr-1 or mmcm-1 protected against toxicity. Therefore, vitamin B12 deficiency does not 
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CHAPTER 1. INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder that is progressive in nature 
and in patients it features loss of memory, communication skills, and cognitive functions such 
as thinking, learning and problem-solving. AD causes brain cells (neurons) in certain areas of 
the brain such as the hippocampus to degenerate. Over time the neurodegeneration spreads to 
much of the frontal and temporal lobes of the cerebral cortex causing loss of synapses and 
eventually leading to brain atrophy (Morrison and Hof 2007; Alzheimer's Association 2019). 
AD is believed to begin two decades before clinical symptoms are seen in patients (Bennett et 
al. 2004).  Although, AD accounts for more than 75% of the cases of dementia in individuals 
over 65 years of age (Erkkinen et al. 2018), it should not be viewed as a normal aspect of 
brain aging.  
AD exists in two form. The Familial AD typically begins between the ages of 30 and 
55 and is referred to as the early onset form accounting for less than 5% of AD cases. The 
late onset form (sporadic AD) is the most prevalent form of AD and begins after 65 years of 
age (Bird 2018). AD development is linked with multiple factors, and in the case of the early 
onset form, has been linked to mutation in three genes: amyloid precursor protein (APP), 
presenilin 1 (PS1) and presenilin 2 (PS2). The greatest risk factors for sporadic AD are aging, 
inheriting the apolipoprotein Ɛ4 allele, and family history (Bekris et al. 2010; Wallon et al. 
2017; Giau et al. 2019). Epidemiological studies have also shown that subjects with 
cerebrovascular disorders, a high cholesterol level, a history of brain injury, diabetes, or mid-
life hypertension are at higher risk of developing AD (Reitz and Mayeux 2014; Prince et al. 
2016). Factors such as gender, level of education, race, and poor diet and lifestyle are 
associated with risk for AD development. (Scheltens et al. 2016). 
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Over 5 million Americans over 65 years of age are living with AD, and by 2050 a 
projected rise to 15.8 million is expected. AD is the 6th leading cause of death in the United 
States and a major cause of poor health and disability in individuals over 65 years of age 
(Alzheimer's Association 2019). The social, economic and financial burden to individuals 
living with AD, the family members who support them, and the nation is on the rise 
(Maresova et al. 2016; Prince et al. 2016). 
Current pharmacological treatment for AD includes acetylcholinesterase inhibitors 
(ACHei) and N-methyl D-aspartate (NMDA) receptor antagonists (Aderinwale et al. 2010). 
However, these treatments provide only mild relief for cognitive function and are used to 
treat cognitive decline at the later stages of the disease. In addition, these drugs are not 
effective in all patients and have substantial side effects (Bianchetti et al. 2006; Small and 
Duff 2008). Non-pharmacological treatments such as exercise and music therapy have been 
found to be mildly effective in some cases. Both, like the pharmaceutical treatments, only 
provide symptomatic relief without stopping AD progression. 
Despite the number of years dedicated towards research to understand the molecular 
and pathological basis of AD no drug has been developed to even slow down its progression 
and almost all drugs have failed clinical trials. AD represents a global challenge to public 
health with impacts on individuals, families, and society at large giving rise to economic and 
social hardship. Due to these devastating consequences there is an increasing need for the 
development of drugs that target novel molecular pathways to attempt to slow down AD 
disease progression. 
Alzheimer’s Disease Pathology 
In the brain, pathophysiology of AD include extracellular deposits of amyloid plaques 
and intracellular aggregation of neurofibrillary tangles (NFTs), which were first described by 
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Alois Alzheimer in 1907 from studying the brain autopsy of AD patients (Murphy and Levine 
2010; Serrano-Pozo et al. 2011). Amyloid plaques contain abnormally folded amyloid-beta 
(Aβ) peptides of 40/42 amino acids in length proteolytically formed from cleavage of 
amyloid precursor protein (APP) (Sheng et al. 2018). Aβ peptides form soluble oligomers and 
then aggregate into beta sheet structures in the neuronal extracellular space and form 
insoluble Aβ plaques. Recent studies posit that intracellular Aβ oligomers are more toxic than 
extracellular Aβ plaques as the oligomers induce neuronal damage and loss of synapses (Tu 
et al. 2014; Ferreira et al. 2015; Ono and Tsuji 2020). Intracellular neurofibrillary tangles are 
helical filaments composed of highly phosphorylated tau proteins, which prevent the 
movements of cargo up and down microtubules in the axons thereby disrupting neuronal 
function (Singh et al. 2016). Both Aβ plaques and tau NFTs inhibit neuronal communication 
via disrupting synapses and consequently lead to neurodegeneration and brain atrophy. 
Hypotheses of AD Development and Progression 
Since the first identification of AD, numerous hypotheses have been put forth to 
explain this multifaceted disorder. The first data-driven molecular hypothesis was postulated 
in 1976 by Peter Davies and A. J. F. Maloney (Davies and Maloney 1976). Behavioral 
changes such as irritability, agitation, depression, and psychosis are often observed at the 
later stage of AD and these are likely coupled with the loss of acetylcholine.  These findings 
led to the cholinergic hypothesis, which posits that deficiency of acetylcholine, a 
neurotransmitter produced by the enzyme choline acetyltransferase at presynaptic clefts, 
causes the behavioral deficits seen in AD patients. Pharmacological therapies such as 
acetylcholinesterase inhibitors, which serve to decrease the rate of acetylcholine degradation, 
have been used to treat late onset AD (Francis et al. 1999; Yiannopoulou and Papageorgiou 
2013; H. Ferreira-Vieira et al. 2016). 
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The amyloid-beta cascade hypothesis has been at the forefront of AD research for the 
past three decades. According to its founders (Hardy and Allsop 1991), the aggregation of Aβ 
peptide , which is a proteolytic product of the transmembrane protein amyloid precursor 
protein (APP), is the major culprit in AD. The downstream effects of Aβ plaque deposition 
result in intracellular neurofibrillary tangle deposition and neuronal and synaptic loss, 
ultimately leading to dementia. The Aβ cascade hypothesis was further corroborated when it 
was found that patients with the familial form of the disease have mutations in genes 
involved in the proteolytic processing of Aβ. The genes involved are APP, PS1 and PS2. 
Also, Down syndrome patients, who possess an extra copy of chromosome 21, have a higher 
risk for developing AD due to location of the APP gene on chromosome 21 (Ricciarelli and 
Fedele 2017). 
As convincing as the amyloid-beta cascade hypothesis seems, many questions are yet 
to be resolved including how increased production of Aβ peptides lead to NFT formation, 
why anti-amyloid therapy has not been able to successfully treat the disease at the clinical 
level, why there are Aβ plaques in the aging brain of patients with no signs of dementia, why 
Aβ plaques and NFTs are seen in patients with late onset AD with no mutation in the APP, 
PS1,or PS2 genes, and how Aβ plaques and NFTs can develop independently of mutations in 
these genes (Swerdlow et al. 2010; Morris et al. 2014; Ricciarelli and Fedele 2017). 
In a bid to explain the pathophysiology of the most common form of AD (sporadic 
late onset AD), the “mitochondrial cascade hypothesis” was put forth. The hypothesis posits 
that mitochondrial dysfunction, which increases with aging leads to decreased oxidative 
phosphorylation and increased reactive oxygen species (ROS) production and that this 
dysfunction drives Aβ deposition and NFT formation. Deposited amyloid-beta peptides are 
imported into mitochondria, where they further increase ROS production and decrease ATP 
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production leading to neuronal cell death (Butterfield 2002; Swerdlow and Khan 2004; 
Swerdlow et al. 2010).  
Other hypotheses for development of AD include the tau hypothesis (Frost et al. 
2009), the calcium hypothesis (Mattson et al. 1992), the metal ion hypothesis (Liu et al. 
2018), the dual pathway hypothesis  (Small and Duff 2008), and the oxidative stress 
hypothesis (Markesbery 1997). An alternative hypothesis recently put forth is the 
homocysteine hypothesis. Homocysteine is a non-protein sulfur containing amino acid, which 
is remethylated to form methionine in the methionine-homocysteine cycle. High serum level 
of homocysteine is an indicator of low B vitamin level (B12, B9, or B6) (Smith et al. 2018).  
The homocysteine hypothesis was formulated to attempt to find a link between the 
cause for the early and late onset forms of AD. Familial AD has been linked with vitamin 
B12 deficiency as mutation in APP gene leads to endolysosomal protease inhibition 
preventing release of vitamin B12 bound to its carrier protein. This is further discussed later 
in the thesis. Likewise, mutation of the presenilin-1 (PS1) gene could disrupt lysosome 
function, preventing the release of cobalamin (vitamin B12) for use by the rest of the cell. 
Several studies have reported high serum homocysteine levels in older subjects before the 
onset of dementia and AD suggesting hyperhomocysteinemia as a risk factor for sporadic AD 
(Regland and McCaddon 2019). 
Mitochondria and AD Development 
Considering the importance of mitochondria as the main energy provider for the cell, 
they have been hypothesized to play a role in AD development and progression and are 
important targets for therapeutic purposes. Mitochondria produce adenosine triphosphate 
(ATP) via oxidative phosphorylation. The electron transport chain (complexes I, II, III, and 
IV) and ATP synthase (complex V) located in the mitochondrial inner membrane generate 
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energy from the NADH and FADH2 produced from the mitochondrial citric acid cycle 
oxidation of respiratory substrates such as pyruvate, fatty acids, and amino acids. 
Cytoplasmic NADH derived from glucose oxidation is also shuttled into the mitochondrial 
matrix space for energy generation. 
Genetic information is present in the mitochondrial matrix space in the form of 
mitochondrial DNA (mtDNA), which can replicate independently of the cell cycle. MtDNA 
is quite susceptible to mutations such as deletions and base substitution mutations. Mutations 
have been shown to accumulate during brain aging and in neurodegenerative disease, to a 
level which can compromise mitochondrial bioenergetics (Tillement et al. 2011). This was 
corroborated in studies that reported mtDNA mutations in neurons in patients with AD (Hirai 
et al. 2001; Wang et al. 2014).   
Also, increased ROS level, reduced ATP production, reduced NADH dehydrogenase 
(complex I) activity, and reduced cytochrome c oxidase (complex IV) activity was reported in 
autopsied AD patient brain mitochondria and in studies that used AD cybrid cell lines, where 
mitochondria from patient blood cells were injected into cell lines depleted of mtDNA, and 
the cells were exposed to A1-40 (Cardoso et al. 2004). β-amyloid oligomers have been 
implicated as the cause of several types of mitochondrial dysfunction. Several studies have 
noted that β-amyloid can be imported across the mitochondrial inner and outer membranes, 
and is able to interact with mitochondrial matrix space molecules (Lustbader et al. 2004; 
Singh et al. 2009).  
A group that used human neuroblastoma cells reported that Aβ1-42 peptide crossed 
the mitochondrial outer membrane and interacted with complex II in the inner membrane 
(Tillement et al. 2006). This is not so surprising given that the mitochondrial outer membrane 
contains oligomeric VDAC proteins that form pores allowing the passage of solutes smaller 
14 
 
than 100 amino acids (~ 10 kD) in size. This study further showed that Aβ1-42 can also 
interact with complexes IV and V of the mitochondrial oxidative phosphorylation machinery. 
Another study also noted a decrease in complex IV (cytochrome oxidase) activity in 
the brain of AD patients (Bosetti et al. 2002). Furthermore, examination of the hippocampus 
of patients with late onset AD revealed decreased cytochrome c oxidase activity (COX) 
compared to normal patients of the same age. Further analysis of the neuronal mtDNA-linked 
COX deficiency found that it was due to elevated mtDNA deletions, which increase with 
aging (Krishnan et al. 2012). 
β-amyloid can further compromise membrane integrity and lead to cell membrane 
deformation, increased membrane permeability (Janson et al., 1999; Engel, 2009) and 
disrupted calcium homeostasis, which can interfere with normal mitochondrial function 
(Csordás et al. 1999). β-amyloid can also impede ATP production via inhibition of oxidative 
phosphorylation (Hauptmann et al. 2009), which consequently increases ROS production 
(Alexeyev et al. 2006). ROS overproduction can lead to DNA damage, lipid peroxidation, 
and cell apoptosis (Tillement et al. 2011). A plethora of evidence has shown a link between 
β-amyloid peptide deposits, mitochondrial dysfunction, and increased oxidative stress 
(Butterfield 2002; Chen and Zhong 2014; Wang et al. 2014; Huang et al. 2016). 
Roles of B Vitamin in Brain Function 
B Vitamins are a group of water-soluble vitamins, which play a role in normal cell 
function by serving as coenzymes/cofactors in enzymatic reactions (Mikkelsen, Stojanovska, 
and Apostolopoulos 2016). They play a role in maintaining mitochondrial energy production, 
the metabolism of protein, fats and carbohydrate, the synthesis of nucleic acids and amino 
acids, as well as play a role in DNA repair and immunity (Laquale 2006; Kennedy 2016). 
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The eight B vitamins with inter-related functions are thiamine (B1), riboflavin (B2), 
niacin (B3), pantothenic acid (B5), pyridoxine (B6), biotin (B7), folate (B9), and cobalamin 
(B12). Except for vitamin B12, which is synthesized only by some bacteria, all other B 
vitamins can be synthesized by plants. B vitamins are derived from dietary supplements of 
plant and animal origin such as meat, grains, fruits, fish, dairy, milk, and vegetables 
(Kennedy 2016). 
Thiamine acts as a cofactor in pathways that are involved in carbohydrate 
metabolism. It plays a role in maintaining neuronal structure and function. Riboflavin and 
niacin function together in mitochondrial energy metabolism. Riboflavin is a precursor for 
two coenzymes, flavin mononucleotide and flavin adenine dinucleotide, while the active 
forms of niacin are nicotinamide adenine dinucleotide (NAD(H)) and NAD phosphate 
(NADP(H)). In addition, riboflavin regulates the recycling of niacin, folate, and vitamin B6 
(pyridoxine). Pantothenic acid is a precursor for the synthesis of coenzyme A and is used in 
the metabolism of amino acids, fatty acids, cholesterols, and phospholipids. Biotin is used in 
carboxylation reactions and is also required for glucose and fatty acid metabolism 
(Mikkelsen, Stojanovska, and Apostolopoulos 2016).  
Vitamin B6, B9, and B12 are involved in one-carbon metabolism of methyl groups, 
which are crucial for the methylation of proteins and nucleic acids. Pyridoxine (B6) serves as 
a cofactor in the folate cycle. Folate (B9) is also important for red blood cell maturation, 
synthesis of DNA, and metabolism of amino acids. Cobalamin (B12) is crucial for the 
synthesis of new red blood cells and for the conversion of folate into its active forms. These 
three vitamins are involved in the folate and methionine cycles, which produce the methyl 
groups required for DNA and RNA methylation. They are also important in lowering the 
plasma level of homocysteine, which is linked to heart disease, stroke, and AD (Kennedy 
2016).  Deficiency of B vitamins is common in the elderly and it is often linked with 
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cardiovascular disorders and neurological disorders such as AD (Mikkelsen, Stojanovska, and 
Apostolopoulos 2016; Smith and Refsum 2016). Daily storage and uptake of up to 1-2 µg of 
vitamin B12 is essential to maintain a healthy vitamin status (Kozyraki and Cases 2013). Ten 
percent of adults over the age of 65 are vitamin B12-deficient due to the loss of intestinal 
uptake with age (Mikkelsen, Stojanovska, Tangalakis, et al. 2016). 
Vitamin B12 Deficiency and AD 
Vitamin B12 (cobalamin) is converted into its two active forms, which are 
adenosylcobalamin in the mitochondrial matrix space and methylcobalamin in the cytoplasm. 
Each is a cofactor for a single enzyme. Adenosylcobalamin is used by the mitochondrial 
enzyme methylmalonyl-CoA mutase and methylcobalamin is used by the cytoplasmic 
enzyme methionine synthase (Morris 2012). Methionine synthase, encoded by the human 
MTR gene and the C. elegans metr-1 gene, catalyzes the synthesis of methionine from 
homocysteine by addition of a methyl group, which is donated by N5-methyl-tetrahydrofolate 
to yield tetrahydrofolate (de Jager 2014). In the mitochondrial matrix, a series of enzymes 
converts propionyl-CoA into D-methylmalonyl-CoA and L-methylmalonyl-CoA 
intermediates. The methylmalonyl-CoA mutase enzyme, encoded by the human MMUT 
(formerly MCM) gene and the C. elegans mmcm-1 gene, with its adenosylcobalamin 
coenzyme, converts L-methylmalonyl-CoA into succinyl-CoA, with the latter being part of 
the citric acid cycle that supplies reducing equivalents for oxidative phosphorylation (Miller 
2003; Birch et al. 2009). Vitamin B12 deficiency leads to the buildup of toxic compounds, 
such as homocysteine and methylmalonic acid, directly upstream of the deficient enzymes 
(Allen 1998; Morris 2012). The measurement of these compounds in the blood is used for the 
diagnosis of vitamin B12 deficiency. 
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One mechanism through which vitamin B12 deficiency may cause dementia is 
through increasing homocysteine levels as decreased cytoplasmic methionine synthase 
activity leads to increased homocysteine levels and increased blood homocysteine is linked 
with AD dementia (Seshadri et al. 2002; Smith and Refsum 2016). A high homocysteine 
level has been suggested to cause increased oxidative stress (Birch et al. 2009), decreased 
DNA methylation, and increased DNA damage, subsequently leading to accumulation of 
amyloid-beta, neurofibrillary tangles, and neuronal cell death (Smith 2008; Smith and 
Refsum 2016). 
Interestingly,  experiments using a C. elegans AD model where  the metr-1 gene was 
knocked down showed an increased level of homocysteine and amyloid-beta toxicity 
(Leiteritz et al. 2018). This might be explained by the fact that hyperhomocysteinemia 
increases amyloid-beta toxicity through the homocysteinylation of peptide lysine residues, 
which leads to the increased formation and stabilization of toxic amyloid-beta oligomers 
(Khodadadi et al. 2012). 
Several lines of study have established that B vitamin deficiency and increased 
plasma homocysteine levels are risk factors for cognitive decline, dementia, and AD. 
However, conflicting results have been reported within the last two decades when vitamins 
B6, B9, and B12, either alone or in combination, have been administered to AD patients. For 
example, a study that examined AD patients, non-demented hospital patients, and healthy 
controls living at home noted that the highest level of homocysteine and methylmalonic acid 
was present in the plasma of AD subjects compared to controls (Joosten et al. 1997). This 
was also confirmed by another group that noted that total serum homocysteine was 
significantly higher, while total serum folate and vitamin B12 were decreased in patients with 
AD dementia when compared to control subjects (Clarke et al. 1998). 
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Others performed an eight-year follow-up study of non-demented elderly who 
participated in the Framingham heart study and reported an increase in plasma homocysteine 
in some subjects with mild dementia, while patients with confirmed cases of AD showed 
higher levels of plasma homocysteine than controls (Seshadri et al. 2002). In contrast, a two-
year study investigated if oral supplementation of folic acid and vitamin B12 could improve 
cognitive function in elderly subjects that had elevated plasma homocysteine and reported 
that there was no improvement in cognitive performance between the group that had been 
given the B vitamin supplement and the group that had received the placebo control. 
However, plasma homocysteine level was significantly reduced in the subjects given the B 
vitamin supplementation compared to the control (Van Der Zwaluw et al. 2014).  A meta-
analysis study of the effects of folate, cobalamin, and vitamin B6 (pyridoxine) 
supplementation on AD patients found that there was a decreased serum homocysteine level 
without an improvement in cognitive function (Zhang et al. 2017). A more recent publication 
that used the above-mentioned B vitamins supplemented to elderly with or without cognitive 
decline also saw no significant improvement in cognition between the treatment group and 
those that were given the placebo. They did however find a significant decrease in 
homocysteine levels in the plasma of subjects supplemented with the B vitamins (Ford and 
Almeida 2019). One possibility is that synapses are irreversibly lost or neurons die shortly 
after the onset of B vitamin deficiency and hyperhomocysteinemia in AD subjects and 
therefore, subsequent recovery of B vitamin levels and lowering of homocysteine levels are 
unable to recover the lost cognitive function. 
Another mechanism through which vitamin B12 deficiency may cause dementia is 
through increasing the level of methylmalonic acid (MMA), which can cause mitochondrial 
electron transport chain dysfunction (Brusque et al. 2002; Chandler et al. 2009; Schuck et al. 
2013). Elevated MMA can occur as a result of deficient vitamin B12-dependent 
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methylmalonyl-CoA mutase enzyme activity within the mitochondrial matrix (Grützner et al. 
2013). Several reports have suggested that MMA causes oxidative stress in mitochondria 
through the accumulation of toxic metabolites, such as propionyl-CoA and propionic acid, 
although their roles in mitochondrial impairment have not been fully elucidated (Haijes et al. 
2019). 
Vitamin B12 Structure and Metabolism 
The chemical structure of Vitamin B12 consists of a cobalt ion, which is the 
functional group, surrounded by a planar corrin ring. Various derivatives of vitamin B12 are 
formed by functional groups which are added to the corrin ring, such as cyanide forming 
cyanocobalamin, a methyl group forming methylcobalamin, or an adenosyl group forming 
adenosylcobalamin.  Cyanocobalamin is a stable synthetic form of vitamin B12 used in 
dietary supplements (Kräutler 2012).  
Many genes are involved in the absorption, transport, binding, and covalent 
modification of cobalamin. Absorption of vitamin B12 occurs in the stomach and small 
intestine. When a meal containing Vitamin B12 is ingested, vitamin B12 binds to haptocorrin 
(also known as transcobalamin 1 (TC1)) in the upper part of the stomach. In the duodenum, 
haptocorrin is degraded and vitamin B12 binds to the intrinsic factor glycoprotein in the 
ileum. In this area of the intestine, the enterocytes synthesize cubulin and amnionless, where 
they localize to the luminal membrane and function to internalize the intrinsic factor-vitamin 
B12 complex within an endosome. Degradation of intrinsic factor occurs within the 
endosome and vitamin B12 binds to another protein called transcobalamin 2 (TC2) and the 
complex is exocytosed into the systemic circulation. Some vitamin B12 in the circulation re-
binds haptocorrin and is unable to be taken up by cells. For vitamin B12 to enter cells, the 
vitamin 12-TC2 complex binds a plasma membrane receptor called CD320 or TCb1R and the 
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entire complex is then endocytosed into the endolysosomal system. In the lysosome, 
proteolytic digestion of TC2 occurs. Mutation in TCN2 has been linked with AD and low 
vitamin B12 status in individuals with autoimmune gastritis. (Surendran et al. 2018).  
Two membrane proteins LMBD1 and ABCD4 are required for the transport of 
cobalamin out of the lysosome. Defects in the genes encoding these proteins will cause 
vitamin B12 to be trapped within the lysosome and unable to be utilized as a coenzyme. Just 
as in these patients with an inborn error of metabolism, defects in lysosomal function in AD 
patients may prevent vitamin B12 from being processed properly into methylcobalamin or 
adenosylcobalamin in neurons leading to the local accumulation of toxic homocysteine and 
methylmalonic acid. But since glial cells may still be able to correctly process vitamin B12 
and metabolize homocysteine and MMA, these toxic products may not increase in the 
bloodstream.  
The MMACHC (methylmalonic aciduria type C and homocysteine) gene product is 
important in conversion of cobalamin into methylcobalamin. This gene encodes the cblC 
protein which is present on the outside of the lysosomal membrane and in the cytoplasm to 
catalyze the conversion of cyanocobalamin, methylcobalamin, or adenosylcobalamin into 
cob(II)alamin, a common intermediate that can be further converted into either 
methylcobalamin or adenosylcobalamin (Surendran et al. 2018). Reduced glutathione is a 
required cofactor for cblC. Glutathione levels are depleted in AD neurons that may perturb 
synthesis of the active forms of vitamin B12. The MMADHC gene locus encodes the cblD 
protein that functions in the partitioning of cob(II)alamin between the cytoplasmic and 
mitochondrial compartments (Gherasim, Hannibal, et al. 2013). Methionine synthase 
reductase also known as the cblE protein encoded by the MTRR gene catalyzes the 
methylation of inactive cob(II)alamin into the active form methylcob(I)alamin (Gherasim et 
al. 2013). The cblA protein encoded by the MMAA gene locus function in the transport of 
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cob(II)alamin into the mitochondrial matrix. The cblB (ATP-dependent cob(I)alamin 
adenosyltransferease) protein is encoded by the MMAB gene locus and functions in the 
synthesis of adenosylcob(I)alamin from cob(II)alamin and S-adenosylmethionine (Oussalah 
et al. 2017). Lastly, adenosylcob(I)alamin functions as a coenzyme for the methylmalonyl-
CoA mutase (MMUT) enzyme, which catalyzes the conversion of methylmalonyl-CoA to 
succinyl-CoA that is used for the production of energy in the tricarboxylic acid cycle 
(Gherasim et al. 2013).   
Since AD is widely understood to be a disease caused by gradual cytoplasmic and 
mitochondrial energy depletion and increased oxidative stress, it is important to discover 
specific molecular mechanisms through which vitamin B12 deficiency may sensitize 
mitochondria and cells to amyloid-beta toxicity. Once this is better understood, targeted 
therapies can be created to restore the levels of the active forms of vitamin B12 to decrease 
homocysteine and methylmalonic acid levels and improve neuronal function to delay the 
onset of the disease. As amyloid plaques can occur up to twenty years before cognitive 
dysfunction, it is important to maintain adequate B vitamin levels starting in middle 
adulthood. 
 Caenorhabditis elegans as a Model Organism  
Use of mammalian models for neurodegenerative disease research has been plagued 
with setbacks ranging from high cost of maintenance to long experiment time. This has led to 
the use of simple and less expensive model organisms to understand the disease mechanism 
with the aim of developing potential drug therapies more rapidly (Chen et al., 2015) 
Caenorhabditis elegans (C. elegans) is a non-parasitic, free-living nematode 
(roundworm) found in the soil that can consume bacteria and fungi as a source of food 
(Barrière and Félix 2014; Corsi et al. 2015). Since it was first introduced by Sydney Brenner 
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in the 1960’s, C. elegans has been shown to be  a good model organism for investigating 
various biological studies ranging from host-microbiota interactions, aging and age-related 
diseases, development, and neurobiology (Kaletta and Hengartner 2006). 
C. elegans is a microscopic organism with a maximum length of 1 mm and a 
simplified anatomy consisting of reproductive, digestive, muscular, and nervous systems, 
which are visible under the microscope due to its transparent body (Culetto and Satelle 2000). 
It has a short life cycle of 4-7 days depending upon the temperature at which it is cultured 
(between 15 and 250 C) and a mean lifespan of 2.5 weeks at 200C (Corsi et al. 2015). In the 
lab, it is typically grown on nematode growth media (NGM) agar in a Petri dish or in 
oxygenated liquid S-media. It is typically fed E. coli bacteria. It generates a large brood size 
and exists mostly as a hermaphrodite, but males are also found at a prevalence of 
approximately 0.1% in the population (Brenner 1974). It can be stored over long periods of 
time in liquid nitrogen. All these characteristics makes it a simple, inexpensive, and effective 
model organism for high throughput screening which has provided the means to elucidate 
molecular mechanisms of disease in a whole organism (Kaletta and Hengartner 2006; Sin et 
al. 2014). 
C. elegans was the first multicellular organism to have its genome sequenced 
(Consortium 1998). About 40-60% of human genes have orthologs in the C. elegans genome 
(Kaletta and Hengartner 2006), while  approximately 42% of genes known to cause human 
diseases such as APP, tau and parkin have orthologs in C. elegans (Culetto and Satelle 2000). 
C. elegans has been used to model neurodegenerative diseases such AD, Parkinson’s disease 
(PD) and Huntington’s disease (HD). This process usually involves gene knockout, 
knockdown, or the creation of a transgenic strain expressing a heterologous human protein 
involved in such diseases (Kaletta and Hengartner 2006; Ma et al. 2018), although 
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CRISPR/Cas9 can also be used to introduce a specific mutation in C. elegans genes to 
engineer a new disease model (Dickinson and Goldstein 2016). 
The ease of genetic manipulation in C. elegans has proven useful in large scale 
genomic screening. RNA interference for gene knockdown is achieved by feeding C. elegans 
with E. coli expressing double stranded RNA (dsRNA), or soaking or injecting the worm 
with dsRNA (Kaletta and Hengartner 2006; Dimitriadi and Hart 2010). Due to the transparent 
body, fluorescent reporter strains of worms have been engineered. In these strains green 
fluorescent protein (GFP) is typically introduced downstream of an endogenous promoter, so 
the expression and tissue localization of that gene can be monitored by fluorescence 
measurements (Teschendorf and Link 2009). Numerous transgenic and knockout strains of C. 
elegans are also available from the University of Minnesota’s Caenorhabditis Genome 
Center (CGC). 
 C. elegans Model of Alzheimer’s Disease 
A strain of C. elegans has been engineered to express human Aβ peptide in the body 
wall muscle. The construct is made of a body wall muscle-specific promoter which drives 
expression of an Aβ1-42 mini-gene fused with an artificial signal peptide from the her-1 gene. 
The transgene plasmid was injected into the C. elegans gonad together with the rol-6 
plasmid, which expresses a mutated collagen gene with a roller marker phenotype causing 
worms to move in a distinctive C shape (Link 1995). 
Aβ expression in C. elegans has been engineered to be inducible or constitutive. The 
former uses a myo-3-specific promoter and a temperature sensitive signal peptide, at which 
upshift of temperature induces Aβ expression causing a relatively quick (within 48 hours) 
paralysis of body wall muscle. In the constitutive expression model, the unc-54 body wall 
muscle-specific promoter drives Aβ expression with a constitutive signal peptide causing 
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paralysis in aged worms  (Teschendorf and Link 2009). The paralysis phenotype in both 
cases is easily scored by observing a lack of body movement in C. elegans or by the 
formation of a halo of cleared bacteria near the head region of the paralyzed worms, as the 
head, neck, and pharyngeal muscles do not become paralyzed. 
A transgenic C. elegans strain expressing amyloid-beta from the snb-1 pan-neuronal 
promoter has also been created (Link 2006). In these worms, one group noted decreased 
chemotaxis and high sensitivity to serotonin with no apparent defect in body movement (Wu 
et al. 2006) 
Some of the drawbacks as regards to the use of C. elegans as a model organism is the 
inability to investigate the molecular pathways that they lack but are present in mammals. 
Also, RNAi is not effective in neurons in most commonly used strains, and human disease 
models of C. elegans don’t fully capture the entire pathophysiology of the disease seen in 
humans (Kaletta and Hengartner 2006; Teschendorf and Link 2009). Low uptake of drugs by 
C. elegans as a result of degradation by their E. coli food source and the  impermeant external 
C. elegans cuticle which prevents drug uptake through the epidermis limits the use of C. 
elegans as a drug discovery model (O’Reilly et al. 2014), although strains with increased 
cuticle permeability have been identified (Xiong et al. 2017). 
C. elegans and a Natural Vitamin B12 Deficient Diet 
Like humans, C. elegans does not synthesize vitamin B12 but must obtain it from the 
diet. E. coli, unlike many other enteric bacteria, lacks the first of three portions of the 
cobalamin synthesis pathway and can only synthesize cobalamin if supplemented with the 
intermediate cobinamide. E. coli take up micronutrients from their LB growth media, a 
peptone and yeast extract-based media containing abundant peptides, fatty acids, simple 
sugars, and micronutrients (Maynard and Weinkove 2020). Two different strains of E. coli 
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are commonly fed to C. elegans in the laboratory. The most common E. coli strain used is 
OP50, while the next most common is HT115(DE3), which was used for the synthesis of the 
two global RNAi libraries.  
It has been shown that the OP50 strain is moderately deficient in vitamin B12 
synthesis due to the lack of the membrane transporter tonB for the uptake of cobalamin 
(MacNeil et al. 2013; Watson et al. 2014). So, when C. elegans feeds on OP50 bacteria, they 
become deficient in vitamin B12, which has been shown to just slightly reduce lifespan, 
fertility and retard growth in C. elegans (Watson et al. 2015). Also, an accumulation of toxic 
intermediates, such as methylmalonic acid and homocysteine, was seen in C. elegans grown 
on vitamin B12-deficient OP50 bacteria (Watanabe et al. 2013). A study by the Revtovich 
group also demonstrated an increased resistance to pathogens, heat, and oxidative stress and 
improved mitochondrial function in C. elegans fed the HT115(DE3) E. coli strain compared 
to worms fed the 0P50 E. coli strain. The increased resistance was eradicated when they 
knocked down the mmcm-1 gene encoding mitochondrial methylmalonyl-CoA mutase, which 
uses vitamin B12 as a cofactor (Revtovich et al. 2019). 
Furthermore, unpublished studies performed by another master’s student from our 
laboratory showed that when C. elegans expressing amyloid-beta in body wall muscle was 
fed with vitamin a B12-deficient OP50 bacterial diet, they became paralyzed more quickly, 
roughly 48 hours after amyloid-beta expression was induced compared to when the C. 
elegans were fed a vitamin B12-rich HT115(DE3) bacterial diet, where they became 
paralyzed roughly 72 hours after amyloid-beta expression was induced. 
Therefore, we hypothesized that vitamin B12-deficiency stimulates amyloid-beta 
toxicity. Consistent with this, a recent report showed that vitamin B12 prevented amyloid-
beta monomer aggregation in a human neuronal cell line (Alam et al. 2017). Thus, following 
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the treatment of vitamin B12-deficient C. elegans expressing amyloid-beta with vitamin B12 
we expected to find a decreased rate of amyloid-beta-induced body wall muscle paralysis. In 
addition, we hypothesized that vitamin B12-deficiency stimulates amyloid-beta toxicity 
through decreasing methylmalonyl-CoA mutase activity and that the addition of 
methylmalonic acid or knocking down the methylmalonyl-CoA mutase gene (mmcm-1) by 
RNAi to increase worm methylmalonic acid levels in vitamin B12-proficient worms will 

















CHAPTER 2. MATERIALS AND METHODS 
C. elegans AD Model   
The C. elegans amyloid-beta expressing strain used for this study was CL4176 [smg-
1(cc546)]; dvIs27, (dvIs27 [myo-3p::A-Beta (1-42)::let-851 3'UTR) + rol-6(su1006)]  
showing temperature-inducible expression of amyloid-beta in body wall muscle when 
upshifted to 250 C. The strain was obtained from University of Minnesota Caenorhabditis 
Genetics Center and reared at 15 0C on Nematode Growth Media (NGM) agar plates and fed 
either the of E. coli OP50-1 strain or the HT115(DE3) strain of E. coli.  
NGM Agar Plate Preparation 
To prepare the NGM agar plates 1.5g NaCl, 8.5 g agar, and 1.25 g peptone were 
dissolved in 500 ml of double deionized water. The solution was autoclaved for 90 minutes 
and allowed to cool down in a 550C water bath for 15 minutes. After cooling, to the media 
was added 500 µl of 1 M CaCl2, 1 M MgSO4, Cholesterol in ethanol 5mg/ml and 12.5 ml of 1 
M KH2PO4 followed by mixing thoroughly. 1 ml of 50 mg/ml ampicillin or streptomycin was 
added to the media based on the strain of E. coli that was grown on the plates. 1 ml of 10 
mg/ml nystatin dissolved in ethanol was added to the media as an antifungal agent. 15 ml of 
the prepared NGM was dispensed to make one 90 mm by 15 mm NGM agar plate. After 
pouring, the plates were placed on a counter to dry and kept in a 150C incubator for future 
use.  
E. coli Food Preparation 
For this project two E. coli strains were used for feeding the worms, OP50 and 
HT115(DE3). Luria-Bertani (LB) broth media was prepared, autoclaved, and completely 
cooled down. The media was then inoculated aseptically with the appropriate strain of E. coli 
(OP50 or HT115(DE3)) and antibiotics, then placed in an incubator shaker and shaken at a 
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speed of 200-250 rpm at 370C for overnight growth (12-18 hrs). The overnight media was 
spun down at 5000g for 10 minutes to obtain the bacterial pellets. The pellets were washed 
three times to remove all traces of LB broth, then weighed and dissolved in sterile double 
deionized H2O at 100 mg/ml concentration. The bacterial food was stored at 4
0C and used for 
up to 3 weeks. NGM agar plates used for the experiments were seeded with the appropriate E. 
coli food fro overnight growth. 
B vitamins Preparation and Concentration 
  Methylcobalamin which is an active form of was used for this study. C. elegans, like 
mammals, can convert methylcobalamin to adenosylcobalamin. Methylcobalamin was diluted 
in deionized water at 200 ng/ml. Vitamin B9 (folic acid) and vitamin B6 (pyridoxal-5’-
phosphate) were dissolved in double deionized water to a final concentration of 25 µM. 500 
µl of the solution containing the compound was added to the surface of 15 ml NGM agar 
plates and allowed to dry in the absence of light before seeding with the appropriate strain of 
E. coli as a food source. 
Amyloid-Beta Peptide Paralysis Assay 
  Before induction of amyloid-beta peptide expression in the CL4176 C. elegans AD 
strain, a two-generation age-synchronization was performed. First, an age synchronization of 
a worm population was obtained by picking 30 gravid worms onto a fresh NGM agar plate 
spread with a lawn of either the E. coli OP50-1 strain or the E. coli HT115(DE3) strain as a 
food source. The NGM agar plates were made with 50 mg/ml of the antibiotic streptomycin 
or ampicillin and 0.01 mg/ml of the antifungal nystatin from a 70% ethanol stock solution. 
The adult worms were left to lay eggs for 2 hours at 200 C, after which the gravid worms 
were removed. The plates were then kept in a 15 0C incubator for one week. On day 7, 8-10 
gravid worms were transferred using a worm pick onto a new NGM agar plate containing the 
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appropriate E. coli strain as food. After laying eggs for 2 hours, gravid worms were removed, 
and the eggs were kept at 15 0C for 48 hours until the nematodes developed into the third 
larval stage (L3). Plates were then transferred to a 25 0C incubator for another 28 hours to 
induce amyloid-beta expression. Worms were then checked every 2 hours for the next 20-24 
hours for paralysis by prodding each one with a worm pick. Paralyzed worms were counted 
as those that ceased motion along at least half the length of their body. To test the protective 
effect of vitamin B12, the appropriate concentration of the drug was added to freshly 
prepared NGM agar plates and allowed to dry overnight, followed by adding 200 µl of 100 
mg/ml 0P50-1 E. coli food, which was incubated  for at least 8 hours at 370 C. For each 
experiment, three plates were used, and each plate had at least 75 nematodes. 
RNAi Interference Experiments 
RNAi experiments were performed using the RNAi feeding method. The 
HT115(DE3) RNAi bacterial clones from the Ahringer and Vidal global RNAi libraries 
contain an L4440 plasmid that possesses a 0.5-1.5 kb insert corresponding to the gene of 
interest, which is flanked on each side by T7 RNA polymerase promoters. 1 mM isopropyl-
D-thiogalactopyranoside (IPTG) was used to induce expression of the T7 RNA polymerase 
gene present in the bacterial genome leading to expression of both strands of the insert on the 
plasmid. For this method we incubated the HT115(DE3) E. coli RNAi-expressing clone with 
IPTG during the last 4 hours of their 16-hour culture in LB media at 370C to induce the 
expression of dsRNA. 50 µg/ml ampicillin added to the culture media.  The overnight media 
was centrifuged for 10 minutes at 5000g. Bacteria was washed up to three times using double 
deionized water (ddw) and resuspended in ddw concentrated at 100 mg/ml and in the 
refrigerator until further use. 
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Knockdown of the vitamin B12-dependent mitochondrial methylmalonyl-CoA mutase 
mmcm-1 gene or the vitamin B12-dependent methionine synthase metr-1 gene was performed 
by using the RNAi feeding method. 25 µg/ml carbenicillin and 1 mM IPTG was added to the 
NGM agar plates. The mmcm-1 and metr-1 E. coli RNAi clones are present in the Vidal 
RNAi library and were obtained from the Dharmacon (Horizon Discovery) company. The 
Aβ-mediated paralysis assays were performed on synchronized C. elegans feeding on the 
metr-1, mmcm-1, or empty vector E. coli RNAi clones. 
Statistical Analysis 
The paralysis assay data was analyzed using Sigma plot version 11.0 software using 
the Kaplan-Meier survival analysis and the Log-Rank test. For each survival curve, the 



















CHAPTER 3. RESULTS 
Effects of Different Diets on Amyloid-Beta Induced Paralysis 
This research investigated a potential protective role of vitamin B12 on amyloid-beta 
induced toxicity in a C. elegans AD model. To induce cobalamin deficiency or proficiency, 
the worms were fed with two different E. coli strains, either the vitamin B12-deficient OP50 
strain or the vitamin B12-proficient HT115(DE3) strain. Following age-synchronization of C. 
elegans feeding on the appropriate diet, a temperature upshift for 30 hours at the third larval 
stage was used to induce amyloid-beta peptide expression in the body wall muscle, which 
leads to paralysis within 48 hours after the temperature upshift. 
 
Figure 1:  CL4176 Amyloid-Beta expressing Worms fed on the HT115 or the OP50  
     E. coli Diet 
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For this experiment, our hypothesis was that the OP50 E. coli diet, which is deficient 
in vitamin B12, will sensitize the worms to amyloid-beta toxicity and the worms would show 
an increased rate of paralysis, while worms fed the vitamin B12-replete HT115 E. coli diet 
will be protected showing a decreased rate of paralysis. The hypothesis was shown to be 
correct as the mean time until paralysis when feeding on HT115 was 16% greater than when 
feeding on OP50 (p<0.001) as shown in Figure 1. 
Vitamin B12 Supplementation When Feeding the OP50 E. coli Diet 
Following the protective effect of the HT115 E. coli diet for delaying paralysis in the 
C. elegans AD model compared to the accelerated paralysis in worms that were fed the OP50 
diet, the OP50 diet was supplemented with 200 ng/ml of methylcobalamin. This was done to 
determine if restoration of vitamin B12 levels could mimic the effect of feeding HT115 E. 
coli to decrease the rate of paralysis and protect against amyloid-beta toxicity. However, 
methylcobalamin addition did not rescue the increased rate of paralysis when worms were fed 




Figure 2:  CL4176 C. elegans fed OP50 in the absence or presence of  
                 Vitamin B12 (200 ng/ml) 
Effects of metr-1 or mmcm-1 Knockdown on the C. elegans AD Model 
It was possible in the previous experiment that the supplemented vitamin B12 was not 
being efficiently taken up or metabolized by C. elegans, thus resulting in the negative result. 
Therefore, further experiments were performed to test if decreased vitamin B12 levels could 
be responsible for the increased toxicity of amyloid-beta peptide when worms were fed the 
OP50 diet.  As mentioned above, the only two enzymes in the C. elegans genome that use 
vitamin B12 as a coenzyme are cytoplasmic methionine synthase (metr-1) and mitochondrial 
methylmalonyl-CoA mutase (mmcm-1). To determine which of these genes may be important 
in the protective effects conferred by the vitamin B12 replete HT115 E. coli diet, RNAi 
knockdown targeting either metr-1 or mmcm-1 was performed. For these RNAi experiments 
the C. elegans were fed on E. coli HT115 carrying either an empty vector, or a vector 
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expressing dsRNA targeted to metr-1 or mmcm-1. If decreased vitamin B12 levels stimulate 
increased amyloid-beta toxicity, then knockdown of one of the two vitamin B12-dependent 
enzymes under vitamin B12 proficient conditions should mimic this effect and increase the 
rate of amyloid-beta-induced paralysis. 
 
 
Figure 3: Effects of mmcm-1 Knockdown on Amyloid-Beta Induced Paralysis in the 





Figure 4: Effects of metr-1 Knockdown on Amyloid-Beta Induced Paralysis in the  
               C. elegans AD Model 
The mean time until paralysis when either mmcm-1 or metr-1 was knocked down was 
20 % greater than the worms fed the HT115 empty vector control E. coli diet with (p<0.001) 
(Figure 3 and Figure 4). Therefore, knockdown of neither of these two vitamin B12-
dependent enzymes increased the rate of amyloid-beta mediated paralysis as hypothesized, 







Vitamin B9 and B6 Supplementation When Feeding the OP50 E. coli Diet 
To determine if other B vitamins of the folate cycle and one-carbon metabolism are 
protective against amyloid-beta toxicity in the C. elegans amyloid-beta toxicity model, 25 
µM of vitamin B9 (folate) or vitamin B6 (pyridoxal-5’-phosphate) was added to the NGM 
agar plate. C. elegans was fed the OP50 E. coli diet, the temperature was upshifted to induce 




Figure 5:  CL4176 C. elegans fed OP50 in the absence or presence of  





Figure 6:  CL4176 C. elegans fed OP50 in the absence or presence of  
                 Pyridoxal-5-phosphate (25 µM) 
Neither vitamin B9 (Figure 5) or vitamin B6 (Figure 6) was able to reduce the rate of 









CHAPTER 4. DISCUSSION 
Deficiency of the B vitamins is common in the elderly and is often linked with 
neurodegenerative disorders such as AD, and cardiovascular disease (Mikkelsen, 
Stojanovska, and Apostolopoulos 2016; Smith and Refsum 2016). Vitamin B6, B9, and B12 
are involved in one carbon metabolism, which is crucial for protein and nucleic acid 
methylation. These three vitamins are also involved in the folate and methionine cycles, 
which are also important for lowering the level of toxic homocysteine in the blood (Kennedy 
2016).   
Over the past three decades, clinical trials administering these vitamins involved in 
one carbon metabolism individually or in combination to treat patients with cognitive decline, 
dementia or AD have reported conflicting results (Joosten et al. 1997; Clarke et al. 1998; 
Seshadri et al. 2002; Zhang et al. 2017; Ford and Almeida 2019). Most recently, the increased 
plasma homocysteine level seen in AD patients was proposed to be a strong, independent risk 
factor for AD (Smith and Refsum 2016). Hyperhomocysteinemia is associated with 
deficiencies of vitamins B6, B9, and B12. Discovering protective roles of vitamins 
functioning in one carbon-metabolism (vitamins B6, B9, and B12) has been a research 
interest to attempt to slow aging and the onset and progression of neurodegenerative diseases. 
This study therefore investigated the effects of vitamin B12 deficiency on amyloid-beta 
toxicity in a C. elegans model of AD. 
Unpublished studies performed by another student from my lab showed that  C. 
elegans fed with vitamin B12-deficient OP50 bacteria as their food became paralyzed more 
quickly, roughly 48 hours after amyloid-beta expression was induced, but C. elegans fed on 
vitamin B12-proficient HT115(DE3) bacteria became paralyzed roughly 72 hours after 
amyloid-beta expression was induced. Differences between the two E. coli diet were also 
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noted in the study performed by the Revtowich group in which there was an increased 
resistance to pathogens, heat, and oxidative stress and improved mitochondrial function in C. 
elegans fed HT115 E. coli compared to those fed 0P50 E. coli (Revtovich et al. 2019). 
C. elegans feeds on different bacteria and fungi in the soil. However, in the laboratory 
their diet is mainly one of two different strains of E. coli. Their most common food source is 
the OP50 strain, which is a B strain of E. coli, and the next most common food source is the 
HT115 strain, which is a K-12 strain of E. coli possessing a mutant RNAse III gene that is 
mostly used for RNAi feeding experiments. The bacterial food source generally provides 
macronutrients such as carbohydrates, proteins, fats, lipids, and nucleic acids, but also 
provides vitamins and other cofactors (Zečić et al. 2019). Both E. coli strains have been 
reported to be composed of different compositions of macro and micronutrients, with HT115 
having a higher carbohydrate composition compared to the OP50 strain (Brooks et al. 2009). 
Nutrition has a significant effect on cellular metabolism and animal health. C. elegans reared 
on these two different E. coli strains exhibited different physiological parameters such as 
lifespan, gene expression profile, fecundity, and growth rate (Stuhr and Curran 2020). The 
OP50 diet has been reported to contain low levels of vitamin B12, which leads to reduced 
fertility and a slow developmental rate without an effect on lifespan (Watson et al. 2014).  
Like humans, but unlike many bacteria, C. elegans must obtain B vitamins from their 
diet. Therefore, to induce vitamin B12 deficiency the worms were first fed either a vitamin 
B12-deficient diet or a vitamin B12-replete diet. It was found that the vitamin B12-deficient 
diet induced an increased rate of amyloid-beta toxicity. Next, since there are several other 
differences in the nutritional makeup of the diets in addition to differences in vitamin B12 
levels, vitamin B12 was added back to the vitamin B12-deficient diet. Surprisingly, adding 
back vitamin B12 did not rescue the increased rate of paralysis. The results therefore suggest 
that the protective effect against amyloid-beta-induced paralysis observed for the worms 
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reared on the HT115 diet is either not related to the vitamin B12 levels in the diet or that the 
supplemented vitamin B12 for some unknown reason was not restoring the activity of the two 
vitamin B12-dependent enzymes. 
Our initial hypothesis was that vitamin B12-deficiency stimulates amyloid-beta 
toxicity and sensitizes mitochondria and cells to amyloid-beta toxicity. Therefore, we 
hypothesized that treatment with vitamin B12 would decrease the established pathological 
hallmarks of the disease. In addition, we hypothesized that vitamin B12-deficiency will 
stimulate amyloid-beta toxicity through decreasing methylmalonyl-CoA mutase activity and 
that knocking down the methylmalonyl-CoA mutase gene (mmcm-1) will increase worm 
methylmalonic acid levels in vitamin B12-proficient worms and stimulate amyloid-beta-
mediated toxicity to mimic the effects of vitamin B12 deficiency. Contrary to our hypothesis, 
results from our knockdown of the mmcm-1 gene showed a decreased paralysis rate 
demonstrating a protective effect.  Likewise, knockdown of the metr-1 gene decreased the 
paralysis rate demonstrating a protective effect. Our results are  in contrast to reports from a 
group that noted an increased rate of paralysis after knockdown of metr-1 in the C. elegans 
CL2006 AD model that constitutively expresses amyloid-beta in body wall muscle (Leiteritz 
et al. 2018). 
 It is likely that activation of the mitochondrial unfolded protein response (UPRmt), 
which can only be robustly induced during larval development, was responsible for the 
protective effects of mmcm-1 and metr-1 knockdown against amyloid-beta toxicity since 
UPRmt induction was shown to protect C. elegans from amyloid-beta toxicity (Sorrentino et 
al. 2018) and deficiency of either mmcm-1 or metr-1 was shown to induce UPRmt (Amin et al. 
2020). It will be important to perform experiments knocking down the mmcm-1 or metr-1 
genes starting from the first day of adulthood, to decrease the activation of the UPRmt, using 
the CL2006 or the similar GMC101 AD strain of worms (Romani et al. 2021). We predict 
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that the knockdown of metr-1 or mmcm-1 would no longer be protective and may even lead 
to an increased rate of paralysis, as shown by others knocking down metr-1 in the CL2006 
strain (Fan and Chiu 2010; Leiteritz et al. 2018) 
Our findings are different from those reported from Revtovich et. al., 2019 in which 
addition of exogenous methylcobalamin to the OP50 diet protected from pathogen, juglone (a 
superoxide generator), peroxide, or heat-induced worm death. In those experiments 
methylcobalamin addition significantly improved C. elegans mitochondrial health by 
increasing mitochondrial fusion and membrane potential. This group also found that mmcm-1 
knockdown in C. elegans prevented the protection conferred by methylcobalamin addition. 
However, they did not study amyloid-beta toxicity, which appears to induce toxicity by a 
different mechanism than the toxic treatments used in the prior study. 
Our results, therefore, do not suggest that vitamin B12 deficiency stimulates amyloid-
beta toxicity and suggest that vitamin B12 deficiency may even protect against amyloid-beta 
toxicity. The results of our study are in part supported by a report (Gagliano Taliun 2019), 
which used Mendelian randomized sampling of data from 6 different studies and found no 
link between low plasma vitamin B12 levels and an increased risk for late onset AD. In 
addition, the rate of AD is lower in India, which due to the high rate of vegetarians in this 
country, has a much higher rate of vitamin B12 deficiency than in the Unites States 
(Mathuranath et al. 2012). It should be determined if vitamin B12 deficiency activates the 
UPRmt in human brain to delay the onset and progression of AD. 
 Homocysteine metabolism is dependent upon one-carbon metabolism, which requires 
vitaminsB6, B12, and B9 (folate). Vitamin B12 and vitamin B9 serve as cofactors in the 
remethylation cycle, which converts homocysteine to methionine, while vitamin B6 is a 
coenzyme in the transsulfuration pathway that converts homocysteine into cysteine, which is 
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not only important for protein synthesis, but is also used for the synthesis of the important 
antioxidant glutathione. (Nieraad et al. 2020). However, the addition of vitamin B9 or B6 did 
not rescue the increased amyloid-beta toxicity that occurs when worms were fed the OP50 E. 
coli diet in the AD worm model. It is likely that amyloid-beta does not affect vitamin B6 or 
B9 metabolism to deplete their levels. So, they are likely already present in sufficient 
amounts so that adding more to the culture media did not have any effect on the enzymes that 
use them as cofactors.  
Conclusion 
This study was not able to demonstrate a link between vitamin B12 deficiency and 
increased Alzheimer’s amyloid-beta-mediated toxicity in C. elegans. In contrast, knockdown 
of either of the two enzymes that utilize vitamin B12 decreased the toxicity of amyloid-beta. 
So, the protection against amyloid-beta toxicity when C. elegans feeds on HT115 compared 
to OP50 E. coli is not due to the increased vitamin B12 levels in the HT115 E. coli, but must 
be due to other differences in the nutrient composition between these two strains. Recent 
studies have shown that the metabolites sucrose, maltose, lactic acid, aspartate, glutamate, 
lysine, GABA (a neurotransmitter), and betaine (involved in one-carbon metabolism) are 
present at higher levels in HT115 than OP50 E. coli and that oleic acid is present at lower 
levels in HT115 than OP50. So, one or more of these nutritional differences may explain the 
protection to C. elegans against amyloid-beta toxicity provided by the consumption of the 
HT115 E. coli diet. Consistent with this hypothesis, betaine was shown to protect C. elegans 
from amyloid-beta toxicity (Leiteritz et al. 2018). GABA was shown to improve cognitive 
function in the APP/PS1 mouse model of AD (Sun et al. 2012) and protect against 





With three of the B vitamins playing essential roles in the one-carbon metabolism 
pathway, it is possible that a deficiency in any one of these three vitamins increases tau 
toxicity, but not amyloid-beta toxicity, to stimulate Alzheimer’s disease. So similar 
experiments could be performed with a C. elegans strain that overexpresses tau protein and 
shows a decreased lifespan. Consistent with this idea, a link has been found between 
increased plasma homocysteine levels and neuronal tau pathology (Regland and McCaddon 
2019). So, more research on B vitamins and AD is needed to determine if any important 
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